دورية أكاديمية
Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
| العنوان: | Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). |
|---|---|
| المؤلفون: | Cherrington AL; Divisions of Preventive and General Internal Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL., Tripputi MT; The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD., Younes N; The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD., Herman WH; Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI., Katona A; Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI., Groessl EJ; Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA., Craig J; University of Cincinnati, Cincinnati, OH., Gonzalez JS; Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY.; Endocrinology, Department of Medicine, and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY., Garg R; Department of Medicine, University of Miami, Miami, FL., Casula S; Endocrinology, Diabetes, and Metabolism, Bruce W. Carter Department of Veterans Affairs Medical Center, Miami, FL., Kuo S; Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI., Florez HJ; Department of Medicine, University of Miami, Miami, FL.; Geriatric Research, Education, and Clinical Center, Bruce W. Carter Department of Veterans Affairs Medical Center, Miami, FL.; Medical University of South Carolina, Charleston, SC. |
| مؤلفون مشاركون: | GRADE Research Group |
| المصدر: | Diabetes care [Diabetes Care] 2024 Apr 01; Vol. 47 (4), pp. 603-609. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Alexandria Va : American Diabetes Association Original Publication: New York, American Diabetes Assn. |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 2*/drug therapy , Metformin*/therapeutic use , Sulfonylurea Compounds*, Humans ; Middle Aged ; Glucose/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Insulin Glargine/therapeutic use ; Liraglutide/therapeutic use ; Quality of Life ; Weight Loss ; Comparative Effectiveness Research |
| مستخلص: | Objective: Diabetes is associated with reduced health-related quality of life (HRQoL). Information on the relationship between HRQoL and glucose-lowering medications in recently diagnosed type 2 diabetes (T2D) is limited. We assessed changes in HRQoL in participants with T2D receiving metformin plus one of four glucose-lowering medications in Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Research Design and Methods: A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin. HRQoL was evaluated at baseline for 4,885 participants, and at years 1, 2, and 3, with use of the self-administered version of the Quality of Well-being Scale (QWB-SA) and SF-36 physical (PCS) and mental (MCS) component summary scales. Linear models were used to analyze changes in HRQoL over time in intention-to-treat analyses. Results: None of the medications worsened HRQoL. There were no differences in QWB-SA or MCS by treatment group at any time point. PCS scores improved with liraglutide versus other groups at year 1 only. Greater weight loss during year 1 explained half the improvement in PCS scores with liraglutide versus glargine and glimepiride. Liraglutide participants in the upper tertile of baseline BMI showed the greatest improvement in PCS scores at year 1. Conclusions: Adding liraglutide to metformin in participants within 10 years of T2D diagnosis showed improvement in the SF-36 PCS in comparisons with the other medications at 1 year, which was no longer significant at years 2 and 3. Improvement was related to weight loss and baseline BMI. (© 2024 by the American Diabetes Association.) |
| References: | Diabetes Res Clin Pract. 2006 Sep;73(3):315-21. (PMID: 16644057) Control Clin Trials. 1989 Dec;10(4):407-15. (PMID: 2691207) Soc Sci Med. 1995 Nov;41(10):1403-9. (PMID: 8560308) Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. (PMID: 36507650) Stat Med. 1997 Jul 15;16(13):1515-27. (PMID: 9249922) N Engl J Med. 2022 Sep 22;387(12):1063-1074. (PMID: 36129996) N Engl J Med. 2022 Sep 22;387(12):1075-1088. (PMID: 36129997) Qual Life Res. 2014 May;23(4):1371-6. (PMID: 24129672) Diabetes Obes Metab. 2019 Mar;21(3):525-532. (PMID: 30260088) Diabet Med. 2022 Jun;39(6):e14825. (PMID: 35253278) Diabetes Obes Metab. 2020 Aug;22(8):1339-1347. (PMID: 32227613) Pharmacoeconomics. 2016 Jul;34(7):645-9. (PMID: 26892973) BMC Public Health. 2021 Nov 3;21(1):1990. (PMID: 34732156) Diabetes Res Clin Pract. 2016 Jun;116:54-67. (PMID: 27321317) J Gen Intern Med. 2012 Dec;27(12):1594-601. (PMID: 22692637) Diabetes Care. 2013 Aug;36(8):2254-61. (PMID: 23690531) Qual Life Res. 2004 Aug;13(6):1153-61. (PMID: 15287281) Soc Sci Med. 1995 Nov;41(10):1383-94. (PMID: 8560306) Diabetes Care. 2019 Nov;42(11):2098-2107. (PMID: 31391203) Health Qual Life Outcomes. 2019 Aug 14;17(1):141. (PMID: 31412881) Value Health. 2013 Sep-Oct;16(6):993-1000. (PMID: 24041349) Clin Obes. 2017 Oct;7(5):273-289. (PMID: 28695722) Health Qual Life Outcomes. 2018 Sep 19;16(1):189. (PMID: 30231882) |
| معلومات مُعتمدة: | UL1 TR000445 United States TR NCATS NIH HHS; U01DK098246 United States DK NIDDK NIH HHS; United States HL NHLBI NIH HHS; UL1 TR002529 United States TR NCATS NIH HHS; P30 DK111022 United States DK NIDDK NIH HHS; UL1 TR000439 United States TR NCATS NIH HHS; P30 DK020541 United States DK NIDDK NIH HHS; UL1 TR002378 United States TR NCATS NIH HHS; UM1 TR004528 United States TR NCATS NIH HHS; P30 DK020572 United States DK NIDDK NIH HHS; UL1 TR002243 United States TR NCATS NIH HHS; UL1 TR002548 United States TR NCATS NIH HHS; U34 DK088043 United States DK NIDDK NIH HHS; UL1 TR002537 United States TR NCATS NIH HHS; P30 DK092926 United States DK NIDDK NIH HHS; UL1 TR002535 United States TR NCATS NIH HHS; P30 DK072476 United States DK NIDDK NIH HHS; P30 DK079626 United States DK NIDDK NIH HHS; UL1 TR001409 United States TR NCATS NIH HHS; U01 DK098246 United States DK NIDDK NIH HHS; UL1 TR001449 United States TR NCATS NIH HHS; UL1 TR002489 United States TR NCATS NIH HHS; U54 GM104940 United States GM NIGMS NIH HHS; UL1 TR001108 United States TR NCATS NIH HHS; UL1 TR002345 United States TR NCATS NIH HHS; R01 DK119282 United States DK NIDDK NIH HHS; P30 DK017047 United States DK NIDDK NIH HHS; United States CC CDC HHS |
| فهرسة مساهمة: | Investigator: JP Crandall; MD McKee; S Behringer-Massera; J Brown-Friday; E Xhori; K Ballentine-Cargill; S Duran; H Estrella; S Gonzalez de la Torre; J Lukin; LS Phillips; E Burgess; D Olson; M Rhee; P Wilson; TS Raines; J Boers; J Costello; M Maher-Albertelli; R Mungara; L Savoye; CA White; C Gullett; L Holloway; F Morehead; S Person; M Sibymon; S Tanukonda; C Adams; A Ross; A Balasubramanyam; R Gaba; E Gonzalez Hattery; A Ideozu; J Jimenez; G Montes; C Wright; P Hollander; E Roe; A Jackson; A Smiley; P Burt; L Estrada; K Chionh; F Ismail-Beigi; C Falck-Ytter; L Sayyed Kassem; A Sood; M Tiktin; T Kulow; C Newman; KA Stancil; B Cramer; J Iacoboni; MV Kononets; C Sanders; L Tucker; A Werner; A Maxwell; G McPhee; C Patel; L Colosimo; A Krol; R Goland; J Pring; L Alfano; P Kringas; C Hausheer; J Tejada; K Gumpel; A Kirpitch; H Schneier; JB Green; H AbouAssi; R Chatterjee; MN Feinglos; J English Jones; SA Khan; JB Kimpel; RP Zimmer; M Furst; BM Satterwhite; CR Thacker; K Evans Kreider; CN Mariash; KJ Mather; HM Ismail; A Lteif; M Mullen; T Hamilton; N Patel; G Riera; M Jackson; V Pirics; D Aguillar; D Howard; S Hurt; R Bergenstal; A Carlson; T Martens; M Johnson; R Hill; J Hyatt; C Jensen; M Madden; D Martin; H Willis; W Konerza; S Yang; K Kleeberger; R Passi; S Fortmann; M Herson; K Mularski; H Glauber; J Prihoda; B Ash; C Carlson; PA Ramey; E Schield; B Torgrimson-Ojerio; K Arnold; B Kauffman; E Panos; S Sahnow; K Bays; K Berame; J Cook; D Ghioni; J Gluth; K Schell; J Criscola; C Friason; S Jones; S Nazarov; J Barzilay; N Rassouli; R Puttnam; B Ojoawo; R Nelson; M Curtis; B Hollis; C Sanders-Jones; K Stokes; Z El-Haqq; A Kolli; T Tran; D Wexler; ME Larkin; J Meigs; B Chambers; A Dushkin; G Rocchio; M Yepes; B Steiner; H Dulin; M Cayford; K Chu; A DeManbey; M Hillard; K Martin; N Thangthaeng; L Gurry; R Kochis; E Raymond; V Ripley; C Stevens; J Park; V Aroda; A Ghazi; M Magee; A Ressing; A Loveland; M Hamm; M Hurtado; A Kuhn; J Leger; L Manandhar; F Mwicigi; O Sanchez; T Young; R Garg; V Lagari-Libhaber; HJ Florez; WM Valencia; J Marks; S Casula; L Oropesa-Gonzalez; L Hue; A Cuadot; R Nieto-Martinez; AK Riccio Veliz; M Gutt; YJ Kendal; B Veciana; A Ahmann; D Aby-Daniel; F Joarder; V Morimoto; C Sprague; D Yamashita; N Cady; N Rivera-Eschright; P Kirchhoff; B Morales Gomez; J Adducci; A Goncharova; SH Hox; H Petrovitch; M Matwichyna; V Jenkins; L Broadwater; RR Ishii; NO Bermudez; DS Hsia; WT Cefalu; FL Greenway; C Waguespack; E King; G Fry; A Dragg; B Gildersleeve; J Arceneaux; N Haynes; A Thomassie; M Pavlionis; B Bourgeois; C Hazlett; S Mudaliar; R Henry; S Boeder; J Pettus; E Diaz; D Garcia-Acosta; S Maggs; C DeLue; A Stallings; E Castro; S Hernandez; J Krakoff; JM Curtis; T Killean; M Khalid; E Joshevama; E Diaz; D Martin; K Tsingine; T Karshner; J Albu; FX Pi-Sunyer; S Frances; C Maggio; E Ellis; J Bastawrose; X Gong; MA Banerji; P August; M Lee; D Lorber; NM Brown; DH Josephson; LL Thomas; M Tsovian; A Cherian; MH Jacobson; MM Mishko; MS Kirkman; JB Buse; J Diner; J Dostou; S Machineni; L Young; K Bergamo; A Goley; J Kerr; JF Largay; S Guarda; J Cuffee; D Culmer; R Fraser; H Almeida; S Coffer; E Debnam; L Kiker; S Morton; K Josey; G Fuller; WT Garvey; AL Cherrington; D Dyer; MCR Lawson; O Griffith; A Agne; S McCullars; RM Cohen; J Craig; MC Rogge; K Burton; K Kersey; C Wilson; S Lipp; MB Vonder Meulen; C Adkins; T Onadeko; N Rasouli; C Baker; E Schroeder; M Razzaghi; C Lyon; R Penaloza; C Underkofler; R Lorch; S Douglass; S Steiner; WI Sivitz; E Cline; LK Knosp; J McConnell; T Lowe; WH Herman; R Pop-Busui; MH Tan; C Martin; A Waltje; A Katona; L Goodhall; R Eggleston; S Kuo; S Bojescu; S Bule; N Kessler; E LaSalle; K Whitley; ER Seaquist; A Bantle; T Harindhanavudhi; A Kumar; B Redmon; J Bantle; M Coe; M Mech; A Taddese; K Lesne; S Smith; C Desouza; L Kuechenmeister; V Shivaswamy; S Burbach; MG Rodriguez; K Seipel; A Alfred; AL Morales; J Eggert; G Lord; W Taylor; R Tillson; DS Schade; A Adolphe; M Burge; E Duran-Valdez; J Martinez; A Bancroft; S Kunkel; F Ali Jamaleddin Ahmad; D Hernandez McGinnis; B Pucchetti; E Scripsick; A Zamorano; RA DeFronzo; E Cersosimo; M Abdul-Ghani; C Triplitt; D Juarez; M Mullen; RI Garza; H Verastiqui; K Wright; C Puckett; P Raskin; C Rhee; S Abraham; LF Jordan; S Sao; L Morton; O Smith; L Osornio Walker; L Schnurr-Breen; R Ayala; RB Kreymer; D Sturgess; KM Utzschneider; SE Kahn; L Alarcon-Casas Wright; EJ Boyko; EC Tsai; DL Trence; S Trikudanathan; BN Fattaleh; BK Montgomery; KM Atkinson; A Kozedub; T Concepcion; C Moak; N Prikhodko; S Rhothisen; TA Elasy; S Martin; L Shackelford; R Goidel; N Hinkle; C Lovell; J Myers; J Lipps Hogan; JB McGill; M Salam; T Schweiger; S Kissel; C Recklein; MJ Clifton; W Tamborlane; A Camp; B Gulanski; SE Inzucchi; K Pham; M Alguard; P Gatcomb; K Lessard; M Perez; L Iannone; E Magenheimer; A Montosa; J Fradkin; HB Burch; AA Bremer; DM Nathan; JM Lachin; H Krause-Steinrauf; N Younes; I Bebu; N Butera; CJ Buys; A Fagan; Y Gao; A Ghosh; MR Gramzinski; SD Hall; E Kazemi; E Legowski; H Liu; C Suratt; M Tripputi; A Arey; M Backman; J Bethepu; C Lund; P Mangat Dhaliwal; P McGee; E Mesimer; L Ngo; M Steffes; J Seegmiller; A Saenger; V Arends; D Gabrielson; T Conner; S Warren; J Day; J Huminik; A Scrymgeour; EZ Soliman; Y Pokharel; ZM Zhang; C Campbell; J Hu; L Keasler; S Hensley; Y Li; R Mihalcea; DJ Min; V Perez-Rosas; L Prosser; L Resnicow; W Ye; H Shao; P Zhang; J Luchsinger; D Sanchez; S Assuras; E Groessl; F Sakha; H Chong; N Hillery; I Abdouch; G Bahtiyar; P Brantley; FE Broyles; G Canaris; P Copeland; JJ Craine; WL Fein; A Gliwa; L Hope; MS Lee; R Meiners; V Meiners; H O'Neal; JE Park; A Sacerdote; E Sledge; L Soni; J Steppel-Reznik; A Turchin |
| المشرفين على المادة: | 6KY687524K (glimepiride) IY9XDZ35W2 (Glucose) 0 (Hypoglycemic Agents) 2ZM8CX04RZ (Insulin Glargine) 839I73S42A (Liraglutide) 9100L32L2N (Metformin) 0 (Sulfonylurea Compounds) |
| تواريخ الأحداث: | Date Created: 20240108 Date Completed: 20240327 Latest Revision: 20240404 |
| رمز التحديث: | 20240404 |
| مُعرف محوري في PubMed: | PMC10973906 |
| DOI: | 10.2337/dc23-1648 |
| PMID: | 38190625 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1935-5548 |
|---|---|
| DOI: | 10.2337/dc23-1648 |